Risks and benefits of cardiac imaging: An analysis of risks related to imaging for coronary artery disease

European Heart Journal

Volumn 35, Issue 10, 2014, Pages 633-638

  Knuuti, Juhani ^a   Bengel, Frank ^b   Bax, Jeroen J ^c   Kaufmann, Philipp A ^d   Le Guludec, Dominique ^e   Perrone Filardi, Pasquale ^f   Marcassa, Claudio ^g   Ajmone Marsan, Nina ^c   Achenbach, Stephan ^h   Kitsiou, Anastasia ⁱ   Flotats, Albert ^j   Eeckhout, Eric ^k   Minn, Heikki ^l   Hesse, Birger ^m  

^a TURKU PET CENTRE   (Finland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g IRCCS   (Italy)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ SISMANOGLIO HOSPITAL   (Greece)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l UNIVERSITY OF TURKU   (Finland)

^m University of Copenhagen   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; GADOLINIUM; INOTROPIC AGENT; IODINATED CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT; VASODILATOR AGENT;

ALLERGIC REACTION; ANGIOCARDIOGRAPHY; BIOLOGICAL ACTIVITY; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; DYNAMIC EXERCISE; EXERCISE TEST; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; REVIEW; RISK BENEFIT ANALYSIS; STRESS ECHOCARDIOGRAPHY;

CARDIAC IMAGING TECHNIQUES; CONTRAST MEDIA; CORONARY ARTERY DISEASE; DRUG COMBINATIONS; EXERCISE TEST; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; RADIATION DOSAGE; RADIATION, IONIZING; RISK ASSESSMENT; STARCH; TALC; TARTRATES;

EID: 84897991778     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht512     Document Type: Review

References (47)

1. Brenner DJ, Hall EJ. Current concepts - computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-2284
2. Lauer MS. Elements of danger - The case of medical imaging. N Engl J Med 2009;361: 841-843
3. Fazel R, Krumholz HM, Wang YF, Ross JS, Chen J, Ting HH, Shah ND, Nasir K, Einstein AJ, Nallamothu BK. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009;361:849-857
4. Organization WH. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. http://whqlibdoc. who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf 2002
5. Myers J, Voodi L, Umann T, Froelicher VF.Asurvey of exercise testing: Methods, utilization, interpretation, and safety in the VAHCS. J Cardiopulm Rehabil 2000;20: 251-258
6. Stuart RJ Jr, Ellestad MH. National survey of exercise stress testing facilities. Chest 1980;77:94-97
7. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384-389
8. Lette J, Tatum JL, Fraser S, Miller DD,Waters DD, Heller G, Stanton EB, Bom HS, Leppo J, Nattel S. Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3-17
9. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-316
10. Lattanzi F, Picano E, Adamo E, Varga A. Dobutamine stress echocardiography: Safety in diagnosing coronary artery disease. Drug Saf 2000;22:251-262
11. Bruder O, Schneider S, Nothnagel D, Dill T, Hombach V, Schulz-Menger J, Nagel E, Lombardi M, Van RossumAC,Wagner A, Schwitter J, Senges J, SabinGV, Sechtem U, Mahrholdt H. EuroCMR (European Cardiovascular Magnetic Resonance) registry: Results of the German pilot phase. J Am Coll Cardiol 2009;54:1457-1466
12. Shellock FG. Radiofrequency energy-induced heating during MR procedures: A review. J Magn Reson Imaging 2000;12:30-36
13. Levine GN, Gomes AS, Arai AE, Bluemke DA, Flamm SD, Kanal E, Manning WJ, Martin ET, Smith JM, Wilke N, Shellock FS. Safety of magnetic resonance imaging in patients with cardiovascular devices: An American Heart Association scientific Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation 2007;116:2878-2891
14. Schaefer DJ, Bourland JD, Nyenhuis JA. Review of patient safety in time-Varying gradient fields. J Magn Reson Imaging 2000;12:20-29
15. Simi S, Ballardin M, Casella M, De Marchi D, Hartwig V, Giovannetti G, Vanello N, Gabbriellini S, Landini L, Lombardi M. Is the genotoxic effect of magnetic resonance negligible? Low persistence of micronucleus frequency in lymphocytes of individuals after cardiac scan. Mutat Res 2008;645:39-43
16. Fiechter M, Stehli J, Fuchs TA, Dougoud S, Gaemperli O, Kaufmann PA. Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity. Eur Heart J 2013;34:2340-2345
17. AndreassiMG, Venneri L, Picano E. Cardiac imaging: The biological effects of diagnostic cardiac ultrasound. Prog Biophys Mol Biol 2007;93:399-410
18. Duck FA. Hazards, risks and safety of diagnostic ultrasound. Med Eng Phys 2008;30: 1338-1348
19. Miller DL, Quddus J. Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. Proc Natl Acad Sci USA 2000;97:10179-10184
20. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for coronary angiography: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999;99:2345-2357
21. Tavakol M, Ashraf S, Brener SJ. Risks and complications of coronary angiography: A comprehensive review. Glob J Health Sci 2012;4:65-93
22. Cohan RH, Ellis JH, Garner WL. Extravasation of radiographic contrast material: Recognition, prevention, and treatment. Radiology 1996;200:593-604
23. Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: A primer for radiologists. Emerg Radiol 2006;12:210-215
24. McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: Executive summary. Rev Cardiovasc Med 2006;7:177-197
25. Nash K, Hafeez A, Hou S. Hospital-Acquired renal insufficiency. Am J Kidney Dis 2002; 39:930-936
26. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51: 1419-1428
27. James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: A systematic review and meta-Analysis. Circ Cardiovasc Interv 2013;6:37-43
28. Main ML, Goldman JH, Grayburn PA. Ultrasound contrast agents: Balancing safety versus efficacy. Expert Opin Drug Saf 2009;8:49-56
29. Asch FM,Weissman NJ. Overview of the 2008 Food and Drug Administration Advisory Committee on safety considerations in the development of ultrasound contrast agents. Circulation 2009;119:1956-1961
30. Document FACB. Definity Premier Database Study. http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4369b1-00-index.html 2008
31. Boyden TF, Gurm HS. Does gadolinium-based angiography protect against contrast-induced nephropathy?: A systematic review of the literature. Catheter Cardiovasc Interv 2008;71:687-693
32. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-469.
33. Kribben A, WitzkeO, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: Pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009;53: 1621-1628
34. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. Am J Roentgenol 2007;189:1533-1538
35. Prince MR, Zhang H, Zou Z, Staron RB, BrillPW. Incidence of immediate gadolinium contrast media reactions. Am J Roentgenol 2011;196:W138-W143
36. Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: A survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656-664
37. Jordan RM, Mintz RD. Fatal reaction to gadopentetate dimeglumine. AJR Am J Roentgenol 1995;164:743-744
38. Silberstein EB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med 1998;39:2190-2192
39. Hesslewood SR, Keeling DH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med 1997;24:1179-1182
40. Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J NuclMed1996;37:185-192
41. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007;168: 1-64
42. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241
43. Directorate-General for Energy and Transport DHNEUH, European Commission. RADIATION PROTECTIONN8 154, European Guidance on Estimating Population Doses from Medical X-Ray Procedure. http://ec.europa.eu/energy/nuclear/radiation- protection/publications-en.htm 2008 (20 March 2013, date last accessed).
44. Protection ICoR. Radiation and your patient: A guide for medical practitioners.Aweb module produced by Committee 3 of the International Commission on Radiological Protection. www.icrp.org/docs/Rad-for-GP-for-web.pdf ed 2011 (20 March 2013, date last accessed)
45. Conroy RM, Pyorala K, FitzgeraldAP, Sans S, Menotti A,DeBacker G,DeBacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A,Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003
46. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008;168:1684-1690; discussion 1691
47. Lifetime odds of death for selected causes. United States 2006. Lifetime odds of death for selected causes. United States 2006. NATIONAL SAFETY COUNCILw INJURY FACTS 2010 EDITION